Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience-Reference-Cited by-同舟云学术

Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience

Published:2019-06-12 Issue: Volume: Page:e12971
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Scalvenzi Massimiliano¹,Villani Alessia¹,Costa Claudia¹,Cappello Milena¹

Affiliation:

1. Department of DermatologyUniversity of Naples Federico II Naples Italy

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.12971

Reference8 articles.

1. Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: A retrospective analysis of efficacy and side effects;Bánvölgyi A.;Journal of Dermatological Treatment,2019

2. Trends in basal cell carcinoma incidence rates: A 37‐year Dutch observational study;Flohil S. C.;The Journal of Investigative Dermatology,2013

3. Characterization and management of Hedgehog pathway inhibitor‐related adverse events in patients with advanced basal cell carcinoma;Lacouture M. E.;Ncologist,2016

4. Neglected skin carcinomas and vismodegib: Our experience;Russo F.;Giornale italiano di dermatologia e venereologia,2018

5. Vismodegib treatment in a HIV positive patient on antiretroviral therapy;Scalvenzi M.;Indian Journal of Dermatology, Venereology and Leprology,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study;Dermatology;2023

2. Real World Data on Efficacy and Safety of Vismodegib in Greek Patients with Advanced, Multiple and Metastatic Basal Cell Carcinoma;Indian Journal of Dermatology;2022-11

3. Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI);Dermatology and Therapy;2019-09-10